Hims & Hers (HIMS) Q4 2025 earnings review
Growth Hits a Wall as the Investment Cycle Deepens
Hims & Hers delivered a solid 28% YoY revenue increase in Q4, but forward guidance reveals a jarring break in trend. Subscriber growth decelerated to 13% YoY, and Q1 2026 guidance implies a staggering slowdown to just ~4.5% YoY revenue growth. Management is aggressively pivoting to international markets—highlighted by the Eucalyptus acquisition and an 825% surge in Rest of World revenue—and investing heavily in new specialties like Labs and Hormones. However, this strategic shift comes at a steep near-term cost: Free Cash Flow reversed to negative in Q4, and Q1 2026 Adjusted EBITDA margin guidance collapsed to 6-9%. The narrative is shifting from hyper-growth to a 'show-me' transition story.
🐂 Bull Case
Rest of the World revenue surged 825% YoY to $63.7M in Q4, validating the recent Zava integration. With the proposed Eucalyptus acquisition (>$450M ARR), Hims is rapidly building a global footprint to offset domestic maturity.
Monthly Revenue per Average Subscriber accelerated to $83, up 11% YoY. The strategy to shift users to higher-priced, personalized multi-condition treatments and GLP-1s continues to bear fruit, masking some of the subscriber volume slowdown.
🐻 Bear Case
Revenue growth is decelerating violently from 111% in 25Q1 to an implied 4.5% in 26Q1. At the same time, subscriber growth slowed to 13% YoY, suggesting customer acquisition is becoming significantly harder or saturated.
Q1 2026 Adjusted EBITDA margin is guided to compress to 6-9%, a sharp reversal from the 16% peak achieved in 25Q1. Elevated marketing, technology, and M&A integration costs are dragging down the bottom line.
⚖️ Verdict: 🔴
Bearish. While the long-term vision of a proactive, global health platform is intact, the near-term metrics are deteriorating rapidly. The sudden halt in top-line momentum, combined with compressing margins and negative free cash flow, creates significant near-term execution risk.
Key Themes
Violent Deceleration in Subscriber Growth
Subscriber additions are decelerating heavily. The company ended Q4 with 2.51 million subscribers, up just 13% YoY. This is a dramatic drop from the 45% YoY growth seen in 24Q4 and 38% in 25Q1. The sequential addition of only 40,000 subscribers from Q3 to Q4 indicates that the core US market customer acquisition engine is losing its exceptional momentum, forcing reliance on ARPU expansion.
Rest of World Firing on All Cylinders
International revenue is accelerating massively, becoming a true growth pillar. Rest of the World revenue hit $63.7M in Q4 (up 825% YoY) and accounted for over 10% of total revenue for the first time. The integration of Zava is clearly working, and the upcoming Eucalyptus acquisition aims to pour gasoline on this fire, shifting Hims from a purely domestic story to a global platform.
Margin Compression Cycle Has Arrived
Management previously telegraphed an investment phase, and it is now showing up in the numbers. Q4 Gross Margin fell to 72% (from 77% a year ago), and G&A/Tech expenses continue to rise. Q1 2026 guidance signals a reversing trend for Adjusted EBITDA, collapsing to a 6-9% margin. The company is actively sacrificing near-term profitability to fund its expansion into Labs, Menopause, and international markets.
Evolving into Proactive Diagnostics
The company's expansion into 'Labs' is a critical strategic pivot. By leveraging personalized biomarker data (over 130 markers), Hims is transitioning from reactive treatment (e.g., hair loss, ED) to proactive longevity and metabolic management. This creates a stickier, higher-LTV ecosystem and moves them closer to becoming a comprehensive primary care alternative rather than a transactional pill dispenser.
Compounded Semaglutide Regulatory Overhang
Management explicitly noted that 2026 guidance 'assumes the ongoing ability to provide access to compounded semaglutide.' With the FDA historically signaling the end of the semaglutide shortage, this remains a massive sword of Damocles. If enforcement discretion ends, Hims will face severe churn as they are forced to transition users to alternative platforms or higher-priced branded options.
Other KPIs
Reversing. FCF turned negative in Q4 compared to $59.5M in the prior year. This was primarily driven by a steep increase in capital expenditures ($59.4M for property, equipment, and intangibles) as the company built out its underlying pharmacy and sterile automation infrastructure. While operating cash flow remains positive ($61.3M), the heavy CapEx burden highlights the capital intensity of vertical integration.
Stable. Up 11% YoY from $75 in Q4 2024. This metric continues to prop up the top line amidst slowing user acquisition, validating the shift toward higher-priced personalized treatments and multi-condition solutions.
Guidance
Decelerating violently. The midpoint of $612.5M implies just ~4.5% YoY growth compared to the $586M delivered in Q1 2025. It also implies a sequential contraction from Q4 2025's $617.8M. This is a severe break in trend from the 111% growth posted a year prior.
Reversing. Compared to the $91.1M (16% margin) achieved in Q1 2025, this represents a severe YoY contraction in profitability. Management is absorbing the costs of new geographic launches and specialty integrations.
Decelerating. The midpoint of $2.8B implies ~19% YoY growth from FY25's $2.35B. Crucially, this guidance explicitly excludes contributions from the Eucalyptus acquisition. However, if Q1 is only growing at 4.5%, this full-year guide implies a massive, back-half-weighted acceleration in organic growth that carries significant execution risk.
Stable annually, but implies a 'hockey stick' recovery. FY25 delivered $318M (14% margin). Achieving the 2026 midpoint of $337.5M will require significant margin expansion in H2 2026 to offset the heavily depressed 6-9% margin guided for Q1.
Key Questions
Bridge the Q1 Revenue Deceleration
Guidance implies roughly 4.5% YoY revenue growth in Q1 2026, dropping sharply from 28% in Q4. How much of this deceleration is driven by the normalization of weight loss shipping cadences versus a fundamental slowdown in core US customer acquisition?
H2 2026 Organic Acceleration
With FY26 revenue guided to ~19% YoY growth but Q1 growing only ~4.5%, your model implies massive organic acceleration in the second half. What are the specific product launches or cohort dynamics underpinning this back-half confidence?
Compounded Semaglutide Contingency
Guidance assumes ongoing access to compounded semaglutide. Given the FDA's regulatory posture, what is the exact financial contingency plan if enforcement discretion ends abruptly in 2026?
Eucalyptus Financial Profile
The Eucalyptus acquisition brings >$450M in ARR but is excluded from guidance. Can you provide color on their margin profile relative to the core business and the expected integration costs once the deal closes mid-year?